Erlotinib beyond progression study: Randomized phase II study comparing chemotherapy plus erlotinib with chemotherapy alone in EGFR tyrosine kinase inhibitor (TKI)-responsive, non-small cell lung cancer (NSCLC) that subsequently progresses.
Balazs Halmos
Research Funding - Astellas Pharma; Astex Therapeutics; Boehringer Ingelheim; Daiichi Sankyo; Lilly; Oncothyreon; Pfizer; Sanofi
Nathan A. Pennell
Research Funding - Oncogenex; Teva
Gregory Alan Otterson
Consultant or Advisory Role - Boehringer Ingelheim; Genentech
Research Funding - Boehringer Ingelheim; Genentech; GlaxoSmithKline; Pfizer; Synta; Tragara Pharmaceuticals
Shirish M. Gadgeel
No relevant relationships to disclose
Tarek Mekhail
Honoraria - Genentech; Lilly
Michael Robert Snell
No relevant relationships to disclose
J. Phillip Kuebler
No relevant relationships to disclose
Pingfu Fu
No relevant relationships to disclose
Neelesh Sharma
No relevant relationships to disclose
Afshin Dowlati
Consultant or Advisory Role - Millennium
Honoraria - Genentech
Research Funding - Amgen; Bristol-Myers Squibb; Genentech; ImClone Systems; Sanofi